Source comparison
9. Sermorelin vs CJC-1295 vs tesamorelin
A practical comparison for UK research protocol design: Pulsatility preservation (sharp, isolated pulses): Sermorelin: best (native-like pulse) CJC-1295 no-DAC: very good (slightly broader pulse) Tesamorelin: good (modestly broader pulse) CJC-1295 with DAC: no
This comparison does not assign a generated winner or score.
- A practical comparison for UK research protocol design:
- Pulsatility preservation (sharp, isolated pulses):
- Sermorelin: best (native-like pulse)
- CJC-1295 no-DAC: very good (slightly broader pulse)
- Tesamorelin: good (modestly broader pulse)
- CJC-1295 with DAC: none (tonic)
- Duration of GH-releasing effect per dose:
- Sermorelin: 60-90 min
- CJC-1295 no-DAC: 60-120 min
- Tesamorelin: 180-240 min
- CJC-1295 with DAC: continuous at steady state
- IGF-1 elevation magnitude at maintenance:
- Sermorelin at 1 µg/kg daily: modest (15-30% above baseline)
- CJC-1295 no-DAC at 100 µg 2-3× daily: moderate (20-40%)
- Tesamorelin 2 mg daily: large (50-100%)
- CJC-1295 with DAC at 1-2 mg weekly: large (50-100%)
- DPP-4 resistance:
- Sermorelin: no (Ala² cleaved rapidly)
- CJC-1295 (both forms): yes (D-Ala² substitution)
- Tesamorelin: yes (trans-3-hexenoyl N-terminal block)